The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in Q4 2025. This will only begin, however, if the US Food and Drug ...

Australia’s Neurizon Therapeutics, a biotech advancing innovative treatments for neurodegenerative diseases, has reported positive top-line results from the Open-Label Extension (OLE) study of its ...

Robin Leaper lost her voice to ALS. Artificial Intelligence has given her back the ability to speak with her own voice.